To: | CHIESI FARMACEUTICI S.P.A. (iplaw@vorys.com) |
Subject: | U.S. TRADEMARK APPLICATION NO. 88226528 - STEBFYBA - 72924-000846 |
Sent: | 3/14/2019 11:01:45 AM |
Sent As: | ECOM120@USPTO.GOV |
Attachments: |
UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO)
OFFICE ACTION (OFFICIAL LETTER) ABOUT APPLICANT’S TRADEMARK APPLICATION
U.S. APPLICATION SERIAL NO. 88226528
MARK: STEBFYBA
|
|
CORRESPONDENT ADDRESS: |
GENERAL TRADEMARK INFORMATION: http://www.gov.uspto.report/trademarks/index.jsp
|
APPLICANT: CHIESI FARMACEUTICI S.P.A.
|
|
CORRESPONDENT’S REFERENCE/DOCKET NO: CORRESPONDENT E-MAIL ADDRESS: |
|
EXAMINER’S AMENDMENT
ISSUE/MAILING DATE: 3/14/2019
DATABASE SEARCH: The trademark examining attorney has searched the USPTO’s database of registered and pending marks and has found no conflicting marks that would bar registration under Trademark Act Section 2(d). TMEP §704.02; see 15 U.S.C. §1052(d).
APPLICATION HAS BEEN AMENDED: In accordance with the authorization granted by Anthony P. Venturino on March 14, 2019, the trademark examining attorney has amended the application as indicated below. Please advise the undersigned immediately of any objections. Otherwise, no response is necessary. TMEP §707. Any amendments to the identification of goods and/or services may clarify or limit the goods and/or services, but may not add to or broaden the scope of the goods and/or services. 37 C.F.R. §2.71(a); see TMEP §§1402.06 et seq.
AMENDMENT TO IDENTIFICATION OF GOODS
The identification of goods is amended to read as follows:
Pharmaceutical preparations and substances for the treatment of pain, cardiovascular disorders, alimentary tract and metabolism problems, respiratory diseases, endocrine, musculoskeletal, cardiopulmonary, genitourinary, oncological, hepatological, ophthalmological, otologicals, neurological, gastrointestinal, hormonal, dermatological and psychiatric related diseases and disorders and for the treatment of damaged skin and tissue; anti-inflammatory and anti-rheumatics drugs; pharmaceutical preparations, namely, immunomodulators; pharmaceutical preparations, namely, hematological agents being pharmaceuticals for the treatment of hematological diseases; Enzyme replacement therapy preparations; Enzyme replacement therapy products, namely, infusions, liquids, tablets and powders for human use in the treatment of genetic disorders for medical purposes; Therapeutic cellular and stem cell compositions for medical use
See TMEP §§1402.01, 1402.01(e).
TRANSLATION STATEMENT
The following statement is added to the record:
The wording “STEBFYBA” has no meaning in a foreign language.
See 37 C.F.R. §2.61(b); TMEP §809.03.
If applicant has questions regarding this Examiner’s Amendment, please telephone or e-mail the assigned trademark examining attorney. All relevant e-mail communications will be placed in the official application record.
/Kara E. Jackson/
Kara E. Jackson
Examining Attorney
Law Office 120
(571)272-4358
Kara.Jackson@uspto.gov
PERIODICALLY CHECK THE STATUS OF THE APPLICATION: To ensure that applicant does not miss crucial deadlines or official notices, check the status of the application every three to four months using the Trademark Status and Document Retrieval (TSDR) system at http://tsdr.gov.uspto.report/. Please keep a copy of the TSDR status screen. If the status shows no change for more than six months, contact the Trademark Assistance Center by e-mail at TrademarkAssistanceCenter@uspto.gov or call 1-800-786-9199. For more information on checking status, see http://www.gov.uspto.report/trademarks/process/status/.
TO UPDATE CORRESPONDENCE/E-MAIL ADDRESS: Use the Trademark Electronic Application System (TEAS) form at http://www.gov.uspto.report/trademarks/teas/correspondence.jsp.